lebrikizumab

Home
Ligands
lebrikizumab

GtoPdb Ligand ID: 7684

Synonyms: Ebglyss® | lebrikizumab-lbkz | MILR1444A | RG3637 | TNX-650

lebrikizumab is an approved drug (EMA (2023), FDA (2024))

Comment: Lebrikizumab is a an anti-IL-13 monoclonal antibody.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.

No information available.

No information available.

Summary of Clinical Use
This antibody was originally tested as a treatment for refractory Hodgkin's lymphoma but was later repurposed as a potential asthma treatment [2]. The antibody entered Phase 2 trial for idiopathic pulmonary fibrosis (IPF) and Phase 3 trial for asthma. Business reports online indicate that Roche have discontinued lebrikizumab development in IPF following mixed results from their trials [1]. Click here to view ClinicalTrails.gov's listing of current lebrikizumab trials. Lebrikizumab was most recently redirected for inflammatory skin conditions. The EMA approved lebrikizumab for the treatment of moderate-to-severe atopic dermatitis in November 2023 [4], with FDA approval for this indication following in September 2024.

Summary of Clinical Use

This antibody was originally tested as a treatment for refractory Hodgkin's lymphoma but was later repurposed as a potential asthma treatment [2]. The antibody entered Phase 2 trial for idiopathic pulmonary fibrosis (IPF) and Phase 3 trial for asthma. Business reports online indicate that Roche have discontinued lebrikizumab development in IPF following mixed results from their trials [1]. Click here to view ClinicalTrails.gov's listing of current lebrikizumab trials. Lebrikizumab was most recently redirected for inflammatory skin conditions. The EMA approved lebrikizumab for the treatment of moderate-to-severe atopic dermatitis in November 2023 [4], with FDA approval for this indication following in September 2024.

Mechanism Of Action and Pharmacodynamic Effects
IL-13 induces airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion in allergic lung diseases such as asthma [7]. These changes contribute to airway obstruction. Lebrikizumab was designed to neutralise circulating IL-13, thereby reducing disease symptoms [6].

Mechanism Of Action and Pharmacodynamic Effects

IL-13 induces airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion in allergic lung diseases such as asthma [7]. These changes contribute to airway obstruction. Lebrikizumab was designed to neutralise circulating IL-13, thereby reducing disease symptoms [6].

External links
For extended ADME data see the following: European Medicines Agency (EMA)

External links

For extended ADME data see the following:

European Medicines Agency (EMA)